Robert N. Fried

All filings by Robert N. Fried on record concern Niagen Bioscience, Inc., in the capacity of chief executive. Over a trading history stretching from 29 January 2016 to 30 June 2026, the count stands at 8 filings.

The open-market side counts 4 purchases for €215k alongside 1 sale. The totals do not cover 1 filing with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 2 option exercises.

Half of the purchases are above €52k and half below. On 2 out of 4 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 8 July 2026 with a share grant (€2,626) in Niagen Bioscience, Inc. The clock since the last published purchase (1 June 2023) now reads 1,235 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.